Trial Profile
Phase II Trial of Extracorporeal Photopheresis (ECP) Plus Low Dose IL-2 for Treatment of Steroid Refractory Chronic Graft-versus-Host Disease (cGVHD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 04 Apr 2024 Status changed from active, no longer recruiting to completed.
- 15 May 2023 Planned End Date changed from 31 Mar 2023 to 31 Dec 2023.
- 15 May 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Dec 2023.